Fredun Pharmaceuticals Ltd

A 265.09% stock return in one year. An 89.6% growth in net profit over the same period. The gap between those two numbers — roughly 175 percentage points — is driven largely by the market's willingness to pay a significantly higher multiple for each rupee of Fredun Pharmaceuticals Ltd's earnings. That premium valuation is the defining feature of this multibagger rally.

Fredun Pharmaceuticals Ltd., a Mumbai-based pharmaceutical formulations manufacturer, delivered an exceptional performance in Q1 FY27 with consolidated net profit surging 93.94% year-on-year to ₹13.13 crores, whilst revenue climbed 90.45% to ₹228.25 crores. The micro-cap company, with a market capitalisation of ₹1,836 crores, saw its stock soar 18.34% following the results announcement, closing at ₹1,313.30 and touching a fresh 52-week high of ₹1,331.70 during intraday trading.

Fredun Pharmaceuticals Ltd has delivered an outstanding financial performance in the quarter ended June 2026, marking a significant improvement in its financial trend from positive to outstanding. The company’s latest quarterly results reveal record-breaking revenue and profit metrics, alongside a notable expansion in operating margins, signalling robust operational efficiency and strategic execution in a challenging market environment.

Extending its winning streak to six consecutive sessions, Fredun Pharmaceuticals Ltd surged to a fresh all-time high of Rs 1,188.45 on 05 Aug 2026, marking a remarkable 20% gain on the day and significantly outpacing the Sensex's modest 0.25% rise.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a new 52-week high of Rs 1156 on 5 Aug 2026, marking a remarkable rally that has seen the stock gain 208.57% over the past year against a Sensex decline of 2.36%. This milestone reflects a powerful momentum driven by a confluence of technical indicators aligning strongly across multiple timeframes.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd reached a fresh 52-week high of Rs 1112 on 4 Aug 2026, marking a remarkable rally of 225.01% over the past year. This milestone comes amid a sustained five-day gain that has propelled the stock 22.69% higher, underscoring strong momentum driven by a confluence of technical indicators and robust price action.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching a new 52-week high of Rs.1033 on 3 August 2026, marking a notable surge in the stock’s momentum amid a strong performance in the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 31 July 2026. This revision primarily stems from a reassessment of its valuation metrics, despite the company’s robust financial performance and strong technical indicators. The new Mojo Score stands at 68.0, reflecting a more cautious stance amid rising price multiples and fair valuation grades.

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade despite delivering exceptional returns over recent years. This recalibration reflects evolving market perceptions amid robust price appreciation and changing price-to-earnings and price-to-book ratios, prompting investors to reassess the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 01 August 2026, providing investors with an up-to-date view of the company’s performance and prospects.

Fredun Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by an improved valuation profile, robust financial trends, and solid quality metrics. The micro-cap pharmaceutical company’s recent performance and comparative valuation against peers have prompted this positive reassessment, signalling growing investor confidence in its long-term prospects.

Fredun Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 16 July 2026. This adjustment reflects a reassessment of the company’s valuation metrics despite its robust financial performance and strong technical indicators. The revised rating is underpinned by changes across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, despite delivering exceptional price returns that have outpaced the broader market. This recalibration reflects evolving market perceptions amid strong operational metrics and a micro-cap status within the Pharmaceuticals & Biotechnology sector.

Surging past the Rs 999 mark today, Fredun Pharmaceuticals Ltd has reached a fresh 52-week high, capping a remarkable rally that has seen the stock more than triple from its low of Rs 296.64 over the past year. This milestone reflects a powerful alignment of technical indicators and sustained price momentum that has propelled the micro-cap pharmaceutical player well ahead of its sector peers.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with the most up-to-date view of the company’s performance and prospects.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a fresh 52-week and all-time high of Rs 2950 on 14 Jul 2026, marking a remarkable rally that has more than tripled the stock price from its 52-week low of Rs 866.05. This milestone reflects a powerful momentum driven by a confluence of technical indicators aligning strongly across multiple timeframes.